Travere anticipates 3-Month PDUFA setback for IgA nephropathy treatmentFDA/Regulatory, TherapeuticsThe FDA is likely to push back the Prescription Drug User Fee Act target action date for Travere Therapeutics’ sparsentan by three months. Read more October 14, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceFDAlogo4-25-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-10-14 09:21:302022-10-14 09:21:30Travere anticipates 3-Month PDUFA setback for IgA nephropathy treatment
